BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis

Results of the reverse phase protein analysis in melanoma cells. The study was performed to identify proteins differentially expressed during drug-induced senescence and drug-induced apoptosis. A375 melanoma cells treated with vehicle, 1μM navitoclax, 1μM alisertib or a combination of both drugs for 24 hrs. Cell pellets were submitted to the MD Anderson Cancer Center RPPA core for lysis and analysis of 447 proteins using reverse phase protein array (RPPA) technology. We analyzed three biological replicates for each treatment condition.